Email Algynomics
Algynomics Home

Algynomics - Personalized Pain Medications and Diagnostics

The Algynomics team has extensive experience and expertise in starting biotechnology businesses, understanding and researching the pathophysiology (including genomics) of pain and associated conditions, designing and conducting clinical trials, and building successful organizations.

  • William Maixner, DDS, PhD

    William Maixner, DDS, PhD, is President of Algynomics and a co-founder of the company. He is a leader in clinical pain research, and Director of the Center for Neurosensory Disorders and Professor of Pharmacology at the University of North Carolina at Chapel Hill. His multidisciplinary research program places high emphasis on translational research and this unit has developed methods that permit the neurological, psychological, and genetic subclassification of chronic pain conditions. Discoveries from his program at UNC are exclusively licensed to Algynomics for the purpose of developing new technologies and methods that enable tailored pain therapies and the identification of new biological targets for future drug development.

  • Luda Diatchenko, MD, PhD

    Luda Diatchenko, MD, PhD, is Chief Scientific Officer of Algynomics and a co-founder of the company. Prior to founding Algynomics, Dr. Diatchenko was leader of the RNA Expression Group at Clontech, Inc., and subsequently Director of Gene Discovery at Attagene, Inc. During this time, Dr. Diatchenko was actively involved in the development of several widely-used molecular tools for the analysis of gene expression and regulation. Dr. Diatchenko is an Associate Professor in the Center for Neurosensory Disorders at the University of North Carolina. Her recent research is focused on determining the cellular and molecular biological mechanisms by which functional genetic variations impact human pain perception and risk of development of chronic pain conditions.

  • Michael A. Hamilton

    Michael A. Hamilton is the Chief Executive Officer of ALG Therapeutics, serves on the Board of Directors for Algynomics, Inc., and is the Managing Director of Triangle BioVentures. He has over 30 years of international pharmaceutical industry experience with emphasis on product strategy, commercialization, and product development. Previously, he held several leadership positions at GlaxoSmithKline including Vice President, Global Commercial Strategy, Infectious Diseases and Vice President, Global Product Strategy, Neurosciences. He led teams through all stages of the drug development process in both R&D and commercial areas. Mr. Hamilton directed global launches of Combivir, Ziagen, Agenerase and Trizivir. He also launched Imitrex in the US. In those roles, he developed long-term disease area strategic plans highlighting commercial opportunities, targeted product profiles, and strategies to optimize franchise success. He holds a BA degree in Chemistry and Psychology from the University of North Carolina at Chapel Hill, and an MBA from Duke University.

  • Roger B. Fillingim, PhD

    Roger B. Fillingim, PhD, is Vice President of Clinical Research Services at Algynomics. Dr. Fillingim is a Professor at the University of Florida College of Dentistry. His research program focuses on biological and psychosocial contributions to individual differences in responses to pain and its treatment. Dr. Fillingim's laboratory has provided important findings regarding the influence of gender, ethnic group, and genetics on pain sensitivity and analgesic responses. Dr. Fillingim received his graduate training in Clinical Psychology at the University of Alabama at Birmingham, including a clinical internship at Duke University Medical Center. He completed a post-doctoral fellowship in pain psychophysics at the University of North Carolina at Chapel Hill.

  • Richard H. Gracely, PhD

    Richard H. Gracely, PhD, is Vice President of Device Development and Pain Measurement. Dr. Gracely received his PhD in experimental psychology from Brown University. He is a Professor in the Center for Neurosensory Disorders at the University of North Carolina and an Adjunct Professor iin the Department of Medicine, Division of Rheumatology at the University of Michigan. His research program focuses on the development and application of human pain measurement methods. These methods have been applied to studies of the mechanisms of pain produced by tissue and/or nerve injury and the mechanisms of pain treatments ranging from analgesic agents to acupuncture and placebo.

  • Gary D. Slade, PhD

    Gary D. Slade, PhD, is Chief Epidemiologist at Algynomics. Dr. Slade obtained his PhD in dentistry at the University of Adelaide and joined the faculty of the University of North Carolina at Chapel Hill in the School of Dentistry and in the School of Public Health. In 2002, he was recruited to the University of Adelaide as Professor of Oral Epidemiology in the School of Dentistry and became director of the Australian Institute of Health and Welfare's Dental Statistics and Research Unit. In 2008-9, he joined the Algynomics team and returned to the University of North Carolina as the John W. Stamm Distinguished Professor of Dentistry in the Department of Dental Ecology. His principal research interests are in population assessment of oral health related quality of life; epidemiological studies of oral disease, orofacial pain and related pain conditions; and public health interventions to prevent oral disease.

  • Jeffrey S. Mogil, PhD

    Jeffrey S. Mogil, PhD, is Vice President of Preclinical Services at Algynomics.  Dr. Mogil is the current E.P. Taylor Professor of Pain Studies (a Chair previously occupied by Dr. Ronald Melzack) and the Canada Research Chair in the Genetics of Pain at McGill University.  Dr. Mogil has made seminal contributions to the field of pain genetics and is a recognized authority in the development and evaluation of pain testing methods in the laboratory mouse.  His research program focuses on the identification of genetic and environmental factors contributing to variability in responses to pain and analgesics, and in the search for more etiologically valid and epidemiologically relevant preclinical pain models.

  • Alex Sleptsov, PhD, MBA

    Alex Sleptsov, PhD, MBA, is Vice President of Corporate Strategy of Algynomics, Inc. He also serves as an Algynomics Board member. As a visiting professor of Strategy, he teaches a wide variety of strategic management courses to the MBA and Executive MBA students at University of Illinois at Urbana-Champaign, Tulane University, and Higher School of Economics (Moscow, Russia). His research, which appeared in Strategic Entrepreneurship Journal and Advances in Mergers and Acquisitions, focuses on acquisitions, strategic alliances, corporate governance, and managing technology and innovation in entrepreneurial companies. In his most recent studies, Dr. Sleptsov explores the effects of the inter-firm and intra-firm information flows in the research-oriented organizations.